Refine
Has Fulltext
- yes (27)
Is part of the Bibliography
- yes (27)
Year of publication
Document Type
- Journal article (27)
Language
- English (27)
Keywords
- glioblastoma (8)
- glioblastoma multiforme (5)
- astrocytoma (4)
- recurrence (4)
- Glioblastoma (3)
- therapy (3)
- CNS disorders (2)
- MPS1 (2)
- blood–brain barrier (2)
- glioma (2)
- low-grade glioma (2)
- mRNA (2)
- organoids (2)
- protein (2)
- relapse (2)
- temozolomide (2)
- vestibular schwannoma (2)
- 3D ex vivo models (1)
- 3D in vitro model (1)
- ADAM9 (1)
- Astrocytic tumor (1)
- Bevacizumab (1)
- CD133 (1)
- CNS diseases (1)
- CXCR4 (1)
- Combination (1)
- EBRT (1)
- Expression (1)
- Glioblastoma cell line (1)
- Glioblastoma multiforme (1)
- Glioma stem cells (1)
- HERV-K (1)
- Human endogenous retrovirus (1)
- IDH (1)
- IDH1/2 (1)
- ISBI (1)
- Immunostimulatory adjuvant (1)
- Immunotherapy (1)
- Irradiation (1)
- MGMT (1)
- MGMT promoter methylation (1)
- Medizin (1)
- Meningioma (1)
- Merlin (1)
- Nestin (1)
- Oncolysis (1)
- Osteopontin (1)
- PCR analysis (1)
- PET/CT (1)
- PRRT (1)
- Pentixafor (1)
- Peptide receptor radionuclide therapy (1)
- RS-13 (1)
- Radiotherapy (1)
- SOAT1 (1)
- Spinal dissemination (1)
- Staphylococcus (1)
- TTFields (1)
- TTK (1)
- Temozolomide (1)
- Tumor Treating Fields (TTFields) (1)
- Tumor-Treating Fields (TTFields) (1)
- \(^{68}\)Ga-Pentixafor (1)
- aging (1)
- amyloidoma (1)
- anticancer activity (1)
- behavior (1)
- blood-brain barrier (1)
- brain (1)
- brain tumor (1)
- cancer stem cells (1)
- chemokine receptor-4 (1)
- chemotherapy (1)
- depression (1)
- diffuse astrocytoma (1)
- distress (1)
- expression (1)
- glioblastoma multiforme (GBM) (1)
- growth pattern (1)
- human brain microvascular endothelial cells (HBMVEC) (1)
- human cells (1)
- imaging (1)
- immunofuorescence double staining (1)
- immunostaining (1)
- in vitro model (1)
- integrin (1)
- internalized stigmatization (1)
- knock down (1)
- lipid droplets (1)
- liponeurocytoma (1)
- liquid biopsy (1)
- lower grade glioma (1)
- mRNA expression (1)
- macrophages (1)
- magnetic resonance imaging (1)
- medulloblastoma (1)
- metastasis (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- microglial cells (1)
- mitotane (1)
- molecular imaging (1)
- molecular signature (1)
- multifocal growth (1)
- nausea and emesis (1)
- neurocytoma (1)
- neurodegenerative disease (1)
- neurooncology (1)
- neurovascular unit (1)
- occupation (1)
- oligodendroglioma (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- pain (1)
- palladium (1)
- pathogenesis (1)
- platinum (1)
- positron emission tomography (1)
- positron emission tomography/computed tomography (1)
- primary cell culture (1)
- prognostic marker (1)
- protein and mRNA expression (1)
- quality of life (1)
- resilience (1)
- resistance (1)
- senescence (1)
- slice culture (1)
- somatostatin (1)
- suppressor (1)
- targeted therapy (1)
- therapy response (1)
- thiosemicarbazone (1)
- tumor slice cultures (1)
- tumormicroenvironment (1)
Institute
- Neurochirurgische Klinik und Poliklinik (24)
- Pathologisches Institut (16)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (3)
- Klinik und Poliklinik für Nuklearmedizin (3)
- Neurologische Klinik und Poliklinik (3)
- Klinik und Poliklinik für Strahlentherapie (2)
- Frauenklinik und Poliklinik (1)
- Institut für Anorganische Chemie (1)
- Institut für Rechtsmedizin (1)
- Kinderklinik und Poliklinik (1)
In a recent study, we showed in an in vitro murine cerebellar microvascular endothelial cell (cerebEND) model as well as in vivo in rats that Tumor-Treating Fields (TTFields) reversibly open the blood–brain barrier (BBB). This process is facilitated by delocalizing tight junction proteins such as claudin-5 from the membrane to the cytoplasm. In investigating the possibility that the same effects could be observed in human-derived cells, a 3D co-culture model of the BBB was established consisting of primary microvascular brain endothelial cells (HBMVEC) and immortalized pericytes, both of human origin. The TTFields at a frequency of 100 kHz administered for 72 h increased the permeability of our human-derived BBB model. The integrity of the BBB had already recovered 48 h post-TTFields, which is earlier than that observed in cerebEND. The data presented herein validate the previously observed effects of TTFields in murine models. Moreover, due to the fact that human cell-based in vitro models more closely resemble patient-derived entities, our findings are highly relevant for pre-clinical studies.